Rezolute/$RZLT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Rezolute
Rezolute Inc is a clinical-stage biopharmaceutical company focused on developing therapies for rare and metabolic diseases. The company aims to address unmet medical needs in conditions like congenital hyperinsulinism, a rare endocrine disorder causing excessive insulin production and resulting hypoglycemia. Rezolute's pipeline includes drug candidates designed to improve patient outcomes while reducing treatment burdens. The company engages in research, development, and clinical trials to advance its therapies and collaborates with medical communities and patient groups to support its objectives. Revenue and value creation depend largely on successful product development and regulatory approvals.
Ticker
$RZLT
Sector
Primary listing
Employees
68
Headquarters
Website
Rezolute Metrics
BasicAdvanced
$525m
-
-$0.80
0.67
-
Price and volume
Market cap
$525m
Beta
0.67
52-week high
$11.46
52-week low
$1.07
Average daily volume
1.9m
Financial strength
Current ratio
15.842
Quick ratio
15.611
Long term debt to equity
0.375
Total debt to equity
0.951
Profitability
EBITDA (TTM)
-85.823
Management effectiveness
Return on assets (TTM)
-48.74%
Return on equity (TTM)
-81.73%
Valuation
Price to book
4.5
Price to tangible book (TTM)
4.5
Price to free cash flow (TTM)
-6.938
Free cash flow yield (TTM)
-14.41%
Free cash flow per share (TTM)
-0.725
Growth
Earnings per share change (TTM)
-27.82%
3-year earnings per share growth (CAGR)
-10.90%
10-year earnings per share growth (CAGR)
-30.15%
What the Analysts think about Rezolute
Analyst ratings (Buy, Hold, Sell) for Rezolute stock.
Rezolute Financial Performance
Revenues and expenses
Rezolute Earnings Performance
Company profitability
Rezolute News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs